# Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

> **NCT03950674** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab 200 mg
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DIETARY_SUPPLEMENT:** Folic acid 350-1000 μg
- **DIETARY_SUPPLEMENT:** Vitamin B12 1000 μg
- **DRUG:** Dexamethasone 4 mg
- **DRUG:** Saline solution

## Key facts

- **NCT ID:** NCT03950674
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-22
- **Primary completion:** 2019-05-20
- **Final completion:** 2023-06-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950674, "Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03950674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*